Premium
The in vivo effects of rhIL‐lα therapy on human monocyte activity
Author(s) -
Lee Anna M.,
VadhanRaj Saroj,
Hamilton Raymond F.,
Scheule Ronald K.,
Holian Andrij
Publication year - 1993
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.54.4.314
Subject(s) - biology , monocyte , in vivo , immunology , microbiology and biotechnology
Pleiotropic cytokines such as interleukin‐lα (IL‐lα) have multiple effects on peripheral blood monocytes (PBMs). This study examined the ability of in vivo recombinant human IL‐lα (rhIL‐lα) therapy to enhance clinically important monocyte functions in ovarian cancer patients prior to chemotherapy. After 4 days of continuous infusion, in vivo rhIL‐lα therapy amplified both the number and activity of PBMs. Therapy with rhIL‐lα increased the number of PBMs sixfold. These monocytes had a significantly increased ability to produce superoxide anion in response to phorbol 12,13‐ dibutyrate stimulation. Their ability to secrete spontaneously the immunomodulatory cytokines IL‐lα and IL‐1β was significantly increased, but their ability to secrete tumor necrosis factor a (TNF‐α) was not significantly elevated. These effects of rhIL‐lα infusion on cytokine secretion by PBMs appear to be related to rhlL‐lα‐in‐ duced increases in the mRNA levels for these cytokines. In contrast, rhIL‐lα therapy did not significantly alter PBM response to lipopolysaccharide (10 μg/ml). In summary, infused rhIL‐lα, in addition to its use as a myelo‐ protective agent, has enhancing effects on the number and activity of PBMs. The effects of rhIL‐lα infusion on PBM function demonstrated here should at least transiently increase the ability of monocytes to combat infection and enhance host immune response.